Subacute pulmonary embolism in a hemodialysis patient, successfully treated with surgical thrombectomy

Abstract

A 53-year-old woman was admitted to our hospital with a 1-month history of gradually progressive resting dyspnea and lumbar backache. For the preceding 6 years, she had received regular hemodialysis for end-stage renal disease caused by autosomal dominant polycystic kidney disease and had taken tamoxifen for 3 years as post-operative chemotherapy for breast cancer. Before admission, the patient’s symptoms had been attributed to volume overload, based on right thoracic fluid and leg edema. However, despite volume correction by dialysis therapy, her symptoms had not improved. The patient was transferred to our hospital, where she was diagnosed with subacute pulmonary embolism (PE). Emergent pulmonary thrombectomy was performed using cardio-pulmonary bypass. The patient was discharged from our hospital on post-operative day 23. Recent reports have shown that hemodialysis patients have a relatively higher risk of PE compared with the general population. Our case had additional risk factors for PE: female sex, decreased protein C level, tamoxifen use, and autosomal dominant polycystic kidney disease. These factors may have had a synergistic effect on the onset of PE.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Tveit DP, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, Welch PG, Abbott KC. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis. 2002;39:1011–7.

    Article  PubMed  Google Scholar 

  2. 2.

    Kumar G, Sakhuja A, Taneja A, Majumdar T, Patel J, Whittle J, Nanchal R. Pulmonary embolism in patients with CKD and ESRD. Clin J Am Soc Nephrol. 2012;7:1584–90.

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Mohan B, Chhabra ST, Aslam N, Wander GS, Sood NK, Verma S, Mehra AK, Sharma S. Mechanical breakdown and thrombolysis in subacute massive pulmonary embolism: a prospective trial. World J Cardiol. 2013;26:141–7.

    Article  Google Scholar 

  4. 4.

    JCS Joint Working Group. Guidelines for the diagnosis treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J. 2011;75:1258–81.

    Article  Google Scholar 

  5. 5.

    Casserly LF, Dember LM. Thrombosis in end-stage renal disease. Semin Dial. 2003;16:245–6.

    Article  PubMed  Google Scholar 

  6. 6.

    Molino D, De Lucia D, Gaspare De Santo N. Coagulation disorders in uremia. Semin Nephrol. 2006;26:46–51.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol. 2008;19:135–40.

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Hernandez RK, Sorensen HT, Pedersen L, Jacobsen J, Lash TL. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer. 2009;115:4442–9.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.

    Article  Google Scholar 

  10. 10.

    Bushnell CD, Goldstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology. 2004;63:1230–3.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Torres VE, Rastogi S, King BF, Stanson AW, Gross JB Jr, Nogorney DM. Hepatic venous outflow obstruction in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994;5:1186–92.

    CAS  PubMed  Google Scholar 

  12. 12.

    Chauveau D, Grunfeld JP, Durand F, Belghiti J. Ascites in a polycystic patient. Nephrol Dial Transplant. 1997;12:228–30.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    O’Sullivan DA, Torres VE, Heit JA, Liggett S, King BF. Compression of the inferior vena cava by right renal cysts: an unusual cause of IVC and/or iliofemoral thrombosis with pulmonary embolism in autosomal dominant polycystic kidney disease. Clin Nephrol. 1998;49:332–4.

    PubMed  Google Scholar 

  14. 14.

    Jacquet A, Pallet N, Kessler M, Hourmant M, Garrigue V, Rostaing L, Kreis H, Legendre C, Mamzer-Bruneel MF. Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int. 2011;24:582–7.

    Article  PubMed  Google Scholar 

  15. 15.

    Maruyama Y, Yamauchi S, Ogasawara H, Imura H, Ochi M, Shimizu K. Surgical experience of subacute pulmonary thromboembolism with severe pulmonary hypertension. Ann Thorac Cardiovasc Surg. 2006;12:60–2.

    PubMed  Google Scholar 

  16. 16.

    Sise ME, Courtwright AM, Channick RN. Pulmonary hypertension in patients with chronic and end-stage kidney disease. Kidney Int. 2013;84:682–92.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Moser KM, Auger WR, Fedullo PF. Chronic major-vessel thromboembolic pulmonary hypertension. Circulation. 1990;81:1735–43.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Nampoory MR, Das KC, Johny KV, Al-Hilali N, Abraham M, Easow S, Saed T, Al-Muzeirei IA, Sugathan TN, Al Mousawi M. Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. Am J Kidney Dis. 2003;42:797–805.

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Kazuhiko Tsuruya.

Ethics declarations

Conflict of interest

Honoraria: Takanari Kitazono (Bayer Pharmaceutical Co., Bristol-Myers Squibb Co., Daiichi-Sankyo Co.), Kazuhiko Tsuruya (Chugai Pharmaceutical Co., Kyowa Hakko Kirin Co.); Takanari Kitazono (Astellas Pharma Inc., Daiichi-Sankyo Co., Eisai Co., Kyowa Hakko Kirin Co., Mitsubishi Tanabe Pharma Co., MSD K.K., Ono Pharmaceutical Co., Otsuka Pharmaceutical Co., Sanofi-Aventis Pharmaceutical Co., Takeda Pharmaceutical Co.), Kazuhiko Tsuruya (Chugai Pharmaceutical Co., Kyowa Hakko Kirin Co., Otsuka Pharmaceutical Co., Takeda Pharmaceutical Co.); Endowed department: Kazuhiko Tsuruya (Baxter).

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yamasaki, K., Haruyama, N., Taniguchi, M. et al. Subacute pulmonary embolism in a hemodialysis patient, successfully treated with surgical thrombectomy. CEN Case Rep 5, 74–77 (2016). https://doi.org/10.1007/s13730-015-0195-9

Download citation

Keywords

  • ADPKD
  • Hemodialysis
  • Pulmonary embolism
  • Tamoxifen